View Older Stories View More Recent Stories
-
Truist on Eli Lilly (LLY): 'We see near-term and longer-term areas for growth'
-
Lilly reports weight loss data for Foundayo across menopause stages
-
Eli Lilly reports positive results for obesity drug retatrutide trials
-
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
-
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
-
ADA 2026 preview: All eyes on these 2 stocks
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
Lilly cuts Germany investment plan in half over healthcare reforms
-
Lilly to present hematology data at European meeting in Stockholm
-
Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
-
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
-
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide
-
CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal
-
Lilly acquires three infectious disease companies for up to $3.83 billion
-
Eli Lilly & Co. (LLY) to buy three vaccine firms for up to $4B - WSJ
-
Lilly's VERVE-102 reduces cholesterol by up to 62% in phase 1b trial
-
Eli Lilly (LLY) PT Raised to $1,251 at BofA Securities
-
Leerink Reiterates Outperform Rating on Eli Lilly (LLY)
-
China holds roundtable with over 50 foreign pharmaceutical firms
-
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
-
Eli Lilly reports weight loss data for obesity drug in older adults
-
Lilly to present oncology data at ASCO 2026 meeting
-
Eli Lilly & Co. (LLY) Acquires Engage Biologics for Up to $202M in Cash
-
Trump to unveil more discounted prescription drug options - CNBC
-
Eli Lilly loses Supreme Court appeal of $194 million fraud award
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly launches Alzheimer's drug in India at $957 per vial
-
Lilly reports weight maintenance with Foundayo and reduced-dose Zepbound
-
FDA Commissioner Marty Makary to step down - Politico
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
Eli Lilly invests additional $4.5 billion in Indiana manufacturing sites
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
Lilly's Omvoh shows sustained disease remission in ulcerative colitis study
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'
-
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
-
Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
-
Bernstein: We're buyers of weakness in LLY
-
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
-
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
Eli Lilly (LLY) PT Lowered to $1,133 at BofA Securities
-
Novo Nordisk rebrands diabetes tablet as Ozempic in US
-
Eli Lilly (LLY) PT Raised to $1,230 at Cantor Fitzgerald
-
Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third week
-
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
-
FDA proposes to exclude semaglutide, tirzepatide from compounding list
-
Lilly surges on earnings beat and raised guidance
-
Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
